GLP-1 receptor agonists may help improve outcomes among women with breast cancer and chronic cardiometabolic diseases, results of a retrospective cohort study suggest.
Women with breast cancer and obesity who used GLP-1 medications exhibited significantly lower risks for all-cause mortality or recurrence than nonusers.
An analysis of women with breast cancer and type 2 diabetes showed similar benefits among GLP-1 users compared with those who used other common antidiabetic medications.
“The initial clinical trials of GLP-1s largely excluded individuals with cancer, and we need to have a better

CHICAGO — An investigational small-molecule oral phosphodiesterase-4 inhibitor appeared well-tolerated and maintained clinical remission rates at 24 weeks among adults in China with ulcerative colitis, according to data presented.
The novel drug, mufemilast (Hemay005, Tianjin Hemay), has been approved in China for patients with plaque psoriasis, but does not have FDA approval.
Results from a recent trial were presented at Digestive Disease Week.
“When looking at this drug, there are some preclinical data that are quite interesting,” presenting author Laurent Peyrin-Biroulet, MD, PhD, head of the